NASDAQ:ONTX - Onconova Therapeutics Stock Price, Price Target & More

$0.5694 -0.01 (-1.73 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$0.5694
Today's Range$0.54 - $0.59
52-Week Range$0.54 - $2.83
Volume421,194 shs
Average Volume358,471 shs
Market Capitalization$11.06 million
P/E Ratio-0.21
Dividend YieldN/A
Beta0.34

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; a license agreement with SymBio Pharmaceuticals Limited; and a strategic collaboration with Cellectar Biosciences, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.49%
Quick Ratio0.49%

Price-To-Earnings

Trailing P/E Ratio-0.21
Forward P/E Ratio-0.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales14.00
Cash FlowN/A
Price / CashN/A
Book Value($1.01) per share
Price / Book-0.56

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-3,061.37%
Return on EquityN/A
Return on Assets-207.61%

Miscellaneous

Employees25
Outstanding Shares19,430,000

How to Become a New Pot Stock Millionaire

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics's stock reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc. (NASDAQ:ONTX) posted its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.10. The biopharmaceutical company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.31 million. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

4 equities research analysts have issued 12-month price objectives for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' stock price to reach $8.00 in the next year. View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (4/19/2018)
  • 2. Maxim Group analysts commented, "Summary We discuss in more detail below the meaning of the Interim analysis and the path to approval, including timelines and costs. Can Onconova get there? There are hurdles (aren’t there for most microcap biotech companies?), but we believe they can eventually, based on the fundamental prospects of Rigosertib." (3/26/2018)
  • 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 838,242 shares, an increase of 55.3% from the March 15th total of 539,610 shares. Based on an average daily trading volume, of 652,121 shares, the short-interest ratio is presently 1.3 days. Approximately 4.9% of the company's shares are short sold.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO, Pres & Director (Age 62)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
  • Dr. Steven M. Fruchtman, Chief Medical Officer and Sr. VP of R&D (Age 67)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
  • Mr. Mark Patrick Guerin, CFO & Principal Accounting Officer (Age 49)

Has Onconova Therapeutics been receiving favorable news coverage?

News headlines about ONTX stock have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Onconova Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.5694.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $11.06 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (ONTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onconova Therapeutics (NASDAQ:ONTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Onconova Therapeutics in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 1,304.99%. The high price target for ONTX is $10.00 and the low price target for ONTX is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.753.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$7.3333$7.3333
Price Target Upside: 1,304.99% upside654.72% upside326.36% upside319.05% upside

Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History

Price Target History for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2018HC WainwrightSet Price TargetBuy$8.00LowView Rating Details
3/26/2018Maxim GroupReiterated RatingHoldLowView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00LowView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Onconova Therapeutics (NASDAQ:ONTX) Earnings History and Estimates Chart

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.41 EPS
Next Year EPS Consensus Estimate: $-1.12 EPS

Onconova Therapeutics (NASDAQ ONTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.63)N/AView Earnings Details
3/8/2018Q4 2017($0.69)($0.59)$0.31 million$0.14 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.73)($0.71)$0.29 million$0.11 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.54)$0.17 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.5910 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Onconova Therapeutics (NASDAQ:ONTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 12.44%
Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)
Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018683 Capital Management, LlcMajor ShareholderBuy200,000$1.04$208,000.00View SEC Filing  
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80385,832View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.905,155View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.604,518,275View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.001,278,718View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.004,307,500View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.0014,935View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Onconova Therapeutics (NASDAQ ONTX) News Headlines

Source:
DateHeadline
BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research ...BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research ...
www.reuters.com - April 20 at 10:16 AM
Onconova Therapeutics (ONTX) Reports Data on Dual Inhibitor of CDK4/6 Plus ARK5 at 2018 AACR MeetingsOnconova Therapeutics (ONTX) Reports Data on Dual Inhibitor of CDK4/6 Plus ARK5 at 2018 AACR Meetings
www.streetinsider.com - April 20 at 10:16 AM
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual MeetingOnconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - April 19 at 10:18 AM
Onconova Therapeutics (ONTX) Stock Rating Lowered by Zacks Investment ResearchOnconova Therapeutics (ONTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 9:05 AM
Onconova readies equity offering; shares down 4% premarketOnconova readies equity offering; shares down 4% premarket
seekingalpha.com - April 18 at 10:18 AM
Onconova Therapeutics (ONTX) Upgraded by Zacks Investment Research to "Buy"Onconova Therapeutics (ONTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 18 at 10:04 AM
Onconova Therapeutics Inc. (ONTX) Receives Average Rating of "Buy" from AnalystsOnconova Therapeutics Inc. (ONTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 16 at 1:42 AM
Onconova Therapeutics Inc. (ONTX) Sees Large Growth in Short InterestOnconova Therapeutics Inc. (ONTX) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 14 at 1:41 AM
Onconova Therapeutics (ONTX) Stock Rating Reaffirmed by Maxim GroupOnconova Therapeutics (ONTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM
Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMTEdited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT
finance.yahoo.com - April 1 at 10:16 AM
Onconova Therapeutics (ONTX) PT Set at $8.00 by HC WainwrightOnconova Therapeutics (ONTX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - March 26 at 1:24 PM
Onconova Therapeutics (ONTX) Given "Hold" Rating at Maxim GroupOnconova Therapeutics (ONTX) Given "Hold" Rating at Maxim Group
www.americanbankingnews.com - March 26 at 1:24 PM
Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease SymposiumOnconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium
finance.yahoo.com - March 26 at 10:57 AM
Onconova Therapeutics Inc (ONTX) Given Consensus Rating of "Buy" by AnalystsOnconova Therapeutics Inc (ONTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 22 at 1:36 AM
Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American ... - GlobeNewswire (press release)Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 3:56 PM
Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - March 15 at 11:01 AM
Onconova Therapeutics (ONTX) Upgraded to "Hold" at ValuEngineOnconova Therapeutics (ONTX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Onconova Therapeutics (ONTX) versus Trius Therapeutics (TSRX) Financial AnalysisOnconova Therapeutics (ONTX) versus Trius Therapeutics (TSRX) Financial Analysis
www.americanbankingnews.com - March 14 at 7:52 PM
Onconova Therapeutics (ONTX) Releases  Earnings Results, Beats Estimates By $0.10 EPSOnconova Therapeutics (ONTX) Releases Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - March 9 at 4:27 PM
Onconova Therapeutics (ONTX) CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOnconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 4:03 PM
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 4:03 PM
Onconova Therapeutics (ONTX) Earns Hold Rating from Maxim GroupOnconova Therapeutics (ONTX) Earns Hold Rating from Maxim Group
www.americanbankingnews.com - March 9 at 1:51 PM
Onconova Therapeutics to Present at the 30th Annual Roth Conference in March - GlobeNewswire (press release)Onconova Therapeutics to Present at the 30th Annual Roth Conference in March - GlobeNewswire (press release)
globenewswire.com - March 6 at 3:50 PM
Onconova (ONTX) Announces License Agreement with Pint Pharma to Commercialize Rigosertib in Latin AmericaOnconova (ONTX) Announces License Agreement with Pint Pharma to Commercialize Rigosertib in Latin America
www.streetinsider.com - March 6 at 10:36 AM
Onconova Therapeutics to Present at the 30th Annual Roth Conference in MarchOnconova Therapeutics to Present at the 30th Annual Roth Conference in March
finance.yahoo.com - March 6 at 10:36 AM
Onconova Announces Presentation of Mechanism of Action Studies ... - GlobeNewswire (press release)Onconova Announces Presentation of Mechanism of Action Studies ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 4:02 PM
Onconova (ONTX) Announces License Agreement with Pint Pharma ... - StreetInsider.comOnconova (ONTX) Announces License Agreement with Pint Pharma ... - StreetInsider.com
www.streetinsider.com - March 5 at 4:02 PM
Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin AmericaOnconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America
finance.yahoo.com - March 5 at 11:13 AM
Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $310,000.00Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $310,000.00
www.americanbankingnews.com - March 3 at 3:08 PM
Onconova Therapeutics (ONTX) Scheduled to Post Earnings on ThursdayOnconova Therapeutics (ONTX) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 2 at 8:10 PM
Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 3:53 PM
Onconova Therapeutics (ONTX) Earns Buy Rating from HC WainwrightOnconova Therapeutics (ONTX) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - March 1 at 12:54 PM
Onconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease SymposiumOnconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium
finance.yahoo.com - March 1 at 10:15 AM
 Analysts Expect Onconova Therapeutics Inc (ONTX) to Post -$0.71 Earnings Per Share Analysts Expect Onconova Therapeutics Inc (ONTX) to Post -$0.71 Earnings Per Share
www.americanbankingnews.com - March 1 at 3:16 AM
Onconova Therapeutics Inc (ONTX) Receives Average Recommendation of "Hold" from BrokeragesOnconova Therapeutics Inc (ONTX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 25 at 1:24 AM
Onconova Announces Two Presentations at 2018 American ... - GlobeNewswire (press release)Onconova Announces Two Presentations at 2018 American ... - GlobeNewswire (press release)
globenewswire.com - February 20 at 3:50 PM
Onconova Announces Two Presentations at 2018 American Chemical Society National Meeting and ExpoOnconova Announces Two Presentations at 2018 American Chemical Society National Meeting and Expo
finance.yahoo.com - February 20 at 9:46 AM
Onconova Therapeutics Announces Closing of $10 Million ... - GlobeNewswire (press release)Onconova Therapeutics Announces Closing of $10 Million ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:00 AM
Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SecuritiesOnconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Securities
finance.yahoo.com - February 13 at 6:00 AM
683 Capital Management, Llc Buys 200,000 Shares of Onconova Therapeutics Inc (ONTX) Stock683 Capital Management, Llc Buys 200,000 Shares of Onconova Therapeutics Inc (ONTX) Stock
www.americanbankingnews.com - February 12 at 6:46 PM
 Brokerages Anticipate Onconova Therapeutics Inc (ONTX) Will Post Earnings of -$0.71 Per Share Brokerages Anticipate Onconova Therapeutics Inc (ONTX) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 12 at 11:30 AM
Reviewing Syndax Pharmaceuticals (SNDX) and Onconova Therapeutics (ONTX)Reviewing Syndax Pharmaceuticals (SNDX) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - February 10 at 9:28 AM
Onconova Therapeutics Announces Pricing of $8.7 Million ... - GlobeNewswire (press release)Onconova Therapeutics Announces Pricing of $8.7 Million ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:19 PM
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at ... - GlobeNewswire (press release)Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at ... - GlobeNewswire (press release)
globenewswire.com - February 3 at 5:50 AM
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research ConferenceOnconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference
finance.yahoo.com - February 2 at 3:20 PM
Onconova Therapeutics Inc (ONTX) Receives Consensus Rating of "Hold" from AnalystsOnconova Therapeutics Inc (ONTX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 31 at 1:34 AM
$310,000.00 in Sales Expected for Onconova Therapeutics Inc (ONTX) This Quarter$310,000.00 in Sales Expected for Onconova Therapeutics Inc (ONTX) This Quarter
www.americanbankingnews.com - January 28 at 4:42 AM
Opiant Pharmaceuticals (OPNT) and Onconova Therapeutics (ONTX) Head to Head ComparisonOpiant Pharmaceuticals (OPNT) and Onconova Therapeutics (ONTX) Head to Head Comparison
www.americanbankingnews.com - January 25 at 1:06 AM
Onconova Therapeutics (ONTX) "Buy" Rating Reiterated at HC WainwrightOnconova Therapeutics' (ONTX) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 18 at 7:00 PM
38 Stocks Moving In Wednesdays Mid-Day Session - Benzinga38 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - January 18 at 4:14 PM

SEC Filings

Onconova Therapeutics (NASDAQ:ONTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.